We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-17.49%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.12B
AUM Growth
-$643M
Cap. Flow
-$73.8M
Cap. Flow %
-3.48%
Top 10 Hldgs %
32.59%
Holding
150
New
6
Increased
39
Reduced
39
Closed
17

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$41.3M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$26.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$12.7M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$12.3M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$30.7M
2
MOH icon
Molina Healthcare
MOH
+$26.6M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$17.3M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15.6M
5
ECYT
Endocyte, Inc. Common Stock
ECYT
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.36%
2 Consumer Staples 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
101
DELISTED
bluebird bio
BLUE
$4.46M 0.21%
3,474
-579
-14% -$888K
MNTA
102
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.42M 0.21%
400,000
-75,000
-16% -$1.04M
ADAP
103
DELISTED
Adaptimmune Therapeutics
ADAP
$4.31M 0.2%
750,000
– –
MRSN
104
DELISTED
Mersana Therapeutics
MRSN
$4.08M 0.19%
40,000
– –
DERM
105
DELISTED
Dermira, Inc.
DERM
$3.72M 0.18%
517,000
-83,000
-14% -$908K
ACHN
106
DELISTED
Achillion Pharmaceuticals
ACHN
$3.7M 0.17%
2,325,000
-75,000
-3% -$212K
ARDX icon
107
Ardelyx
ARDX
$997M
$3.58M 0.17%
2,000,000
-525,557
-21% -$1.55M
DVAX
108
DELISTED
Dynavax Technologies
DVAX
$3.48M 0.16%
380,000
+112,000
+42% +$1.24M
ACET icon
109
Adicet Bio
ACET
$74.7M
$3.45M 0.16%
3,571
– –
CMTA
110
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$3.23M 0.15%
275,000
-70,000
-20% -$871K
SPRO icon
111
Spero Therapeutics
SPRO
$73M
$3.23M 0.15%
525,000
– –
CORV
112
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$2.99M 0.14%
1,200,000
– –
LJPC
113
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.61M 0.12%
277,236
-4,564
-2% -$68.7K
PHAS
114
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.58M 0.12%
+835,000
New +$3.31M
CGEN icon
115
Compugen
CGEN
$228M
$2.39M 0.11%
1,100,000
+21,835
+2% +$69.2K
NBRV
116
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.34M 0.11%
6,400
-800
-11% -$430K
PRTK
117
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.31M 0.11%
450,000
– –
ARVN icon
118
Arvinas
ARVN
$572M
$1.93M 0.09%
150,000
– –
GTHX
119
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.92M 0.09%
100,000
-133,073
-57% -$4.98M
CHMA
120
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.63M 0.08%
525,000
– –
SLDB icon
121
Solid Biosciences
SLDB
$900M
$1.58M 0.07%
3,933
-2,400
-38% -$1.13M
CRVS icon
122
Corvus Pharmaceuticals
CRVS
$1.17B
$1.47M 0.07%
400,000
-175,000
-30% -$1.19M
KA
123
DELISTED
Kineta, Inc. Common Stock
KA
$1.3M 0.06%
+2,857
New +$1.94M
MGNX icon
124
MacroGenics
MGNX
$257M
$1.03M 0.05%
80,981
-194,019
-71% -$3.25M
ABBV icon
125
AbbVie
ABBV
$435B
– –
-325,000
Closed -$30.7M
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Rock Springs Capital Management held 150 positions worth $2.12B, down 23% from $2.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rock Springs Capital Management withdrew a net $73.8M in Q4 2018, closing 17 positions and reducing 39 holdings. Its most notable exit was AbbVie, an estimated $30.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 90% a quarter earlier, followed by Consumer Staples.

Against the trend, Rock Springs Capital Management opened a new position in Seagen Inc. Common Stock worth $11.5M.

  • Rock Springs Capital Management's largest Q4 2018 buy was Seagen Inc. Common Stock: 202,500 shares worth $11.5M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q4 2018, an estimated $41.3M increase.
  • Rock Springs Capital Management's biggest Q4 2018 reduction was Molina Healthcare, cutting an estimated $26.6M.
  • Rock Springs Capital Management fully exited AbbVie in Q4 2018, selling an estimated $30.7M.
  • Rock Springs Capital Management's ten largest holdings make up 33% of its $2.12B portfolio in Q4 2018.
  • Rock Springs Capital Management opened 6 new positions and closed 17 in Q4 2018.
  • Rock Springs Capital Management's portfolio value fell 23% quarter-over-quarter to $2.12B.

Based on Rock Springs Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.